Ian Sanne to HIV Protease Inhibitors
This is a "connection" page, showing publications Ian Sanne has written about HIV Protease Inhibitors.
Connection Strength
0,459
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.
Score: 0,199
-
Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
Score: 0,130
-
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006 May; 28(5):745-54.
Score: 0,063
-
Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004 Apr 30; 18(7):1084-5.
Score: 0,055
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
Score: 0,013